U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H37N3O7S
Molecular Weight 547.6657
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DARUNAVIR

SMILES

CC(C)CN(C[C@]([H])([C@]([H])(Cc1ccccc1)N=C(O)O[C@@]2([H])CO[C@]3([H])[C@@]2([H])CCO3)O)S(=O)(=O)c4ccc(cc4)N

InChI

InChIKey=CJBJHOAVZSMMDJ-HEXNFIEUSA-N
InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H37N3O7S
Molecular Weight 547.6657
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23708741 | http://adisinsight.springer.com/drugs/800016726

Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.5 pM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PREZISTA

Approved Use

PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents.

Launch Date

1.15102083E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5272 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
93026 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
124698 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
57055 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
126377 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5%
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Disc. AE: Headache, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Headache (grade 3, 0.79%)
Gastrointestinal disorder NOS (5.51%)
Sources: Page: p.227
3200 mg single, oral
Overdose
Dose: 3200 mg
Route: oral
Route: single
Dose: 3200 mg
Sources: Page: p.22
healthy
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Disc. AE: Drug-induced hepatitis, Hepatitis acute...
AEs leading to
discontinuation/dose reduction:
Drug-induced hepatitis
Hepatitis acute
Cytolytic hepatitis
Reaction skin (grade 1-3)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Diabetes mellitus
Hyperglycemia
Fat redistribution
Fat tissue increased
Immune reconstitution syndrome
Sources: Page: p.1
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 1-2, 0.5%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disorder NOS 5.51%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Headache grade 3, 0.79%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Cytolytic hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Diabetes mellitus Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Drug-induced hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat redistribution Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat tissue increased Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hepatitis acute Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hyperglycemia Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Immune reconstitution syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Stevens-Johnson syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Toxic epidermal necrolysis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Reaction skin grade 1-3
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Rash grade 1-2, 0.5%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
PubMed

PubMed

TitleDatePubMed
TMC-114 (Tibotec).
2004 Aug
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
2004 Jul-Sep
Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114).
2004 Nov 12
Anti-HIV agents. What the future holds for TMC114.
2005 Aug-Sep
Anti-HIV agents. Interactions with TMC114.
2005 Aug-Sep
Anti-HIV agents. TMC114--an overview.
2005 Aug-Sep
Development of a capillary electrophoretic method for the separation of diastereoisomers of a new human immunodeficiency virus protease inhibitor.
2005 Feb
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
2005 Mar 24
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
2005 Mar 24
New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.
2005 Mar-Apr
New PI may offer hope to triple class patients.
2005 May
Report from the 13th retrovirus conference. New data on TMC114 and TMC125.
2006 Apr
FDA clears HIV drug for patients with resistant virus.
2006 Aug
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
2006 Feb 23
Prezista (darunavir, TMC-114) approved; may be important treatment advance.
2006 Jan-Jun
FDA approves new PI.
2006 Jun
The clinical pharmacology of antiretrovirals in development.
2006 Jun
Drug interactions. Interactions with TMC114 and TMC125.
2006 Jun-Jul
XVI International AIDS Conference: Part 2.
2006 Nov
TMC114 approved for resistant patients.
2006 Oct
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
2007
AIDS in the Third World: how to stop the HIV infection?
2007
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
2007 Apr 1
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
2007 Apr 7
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
2007 Feb 19
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
2007 Jan
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
2007 Jul 11
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
2007 Jul 7
Prezista gets EU approval.
2007 Mar
Tibotec and Aspen collaborate on Prezista.
2007 May
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
2007 May
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
2007 May 31
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
2007 Sep 1
Tipranavir: a new option for the treatment of drug-resistant HIV infection.
2007 Sep 15
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
2007 Sep 28
Quality control of protease inhibitors.
2008 Jun
Patents

Sample Use Guides

Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (two 400 mg tablets) taken with ritonavir 100 mg once daily and with food. Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of PREZISTA and ritonavir is based on body weight and should not exceed the treatmentexperienced adult dose. Do not use once daily dosing in pediatric patients. PREZISTA should be taken with ritonavir twice daily and with food.
Route of Administration: Oral
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL). Darunavir demonstrates antiviral activity in cell culture against a broad panel of HIV-1 group M (A, B, C, D, E, F, G), and group O primary isolates with EC50 values ranging from less than 0.1 to 4.3 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:36:48 UTC 2021
Edited
by admin
on Fri Jun 25 21:36:48 UTC 2021
Record UNII
YO603Y8113
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DARUNAVIR
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DARUNAVIR [WHO-DD]
Common Name English
((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER
Common Name English
DARUNAVIR [MART.]
Common Name English
TMC114
Code English
DARUNAVIR [USAN]
Common Name English
DARUNAVIR [ORANGE BOOK]
Common Name English
DARUNAVIR [INN]
Common Name English
DRV
Common Name English
DARUNAVIR [MI]
Common Name English
DARUNAVIR [EMA EPAR]
Common Name English
TMC-41629
Code English
DARUNAVIR [HSDB]
Common Name English
TMC-114
Code English
DARUNAVIR [VANDF]
Common Name English
UIC-94017
Code English
TMC 114
Code English
Classification Tree Code System Code
WHO-ATC J05AE10
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
LIVERTOX 268
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
NDF-RT N0000175889
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
WHO-ATC J05AR14
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
NDF-RT N0000000246
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
WHO-VATC QJ05AE10
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
NCI_THESAURUS C783
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
Code System Code Type Description
CAS
206361-99-1
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
EPA CompTox
206361-99-1
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
NDF-RT
N0000190114
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
LACTMED
Darunavir
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
WIKIPEDIA
DARUNAVIR
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
INN
8305
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
HSDB
7788
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
ChEMBL
CHEMBL1323
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
FDA UNII
YO603Y8113
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
MERCK INDEX
M4099
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY Merck Index
EVMPD
SUB25394
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
NCI_THESAURUS
C65364
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
DRUG CENTRAL
4143
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
DRUG BANK
DB01264
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
RXCUI
460132
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY RxNorm
PUBCHEM
213039
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
MESH
C482292
Created by admin on Fri Jun 25 21:36:48 UTC 2021 , Edited by admin on Fri Jun 25 21:36:48 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC